Revolution Medicines Inc at Barclays Lunchtime Biotech Fireside Chat Series Transcript
Good afternoon. My name is Peter Lawson. I'm one of the biotech analysts at Barclays. Welcome to Lawson's Lunchtime Deep Dive with Revolution Medicines. Goal of these calls is to help preview upcoming data and we've been doing it for the last 3 years at Barclays and Revolution Medicines [attending] our series, and I think we've got the 4 left this year for the series.
And I hope you find them useful and of course, [II season] and so we very much appreciate all those are support. And just as a way of orientation, this is a 30-minute call, if you have questions, do e-mail me directly. So at [email protected], you can get me on Bloomberg. I'm on Bloomberg, so you can pass me that way.
And -- the others -- and it gives me great pleasure here to introduce Revolution Medicines. We don't cover the company, so uncovered. So thanks so much, Mark Goldsmith, CEO. Thanks for your time today and you have time permitting, we'd love to cover the multi-RAS inhibitor updated data in the second half and then your G12C.
| Access to All Earning Calls and Stock Analysis | |
| 30-Year Financial on one screen | |
| All-in-one Stock Screener with unlimited filters | |
| Customizable Stock Dashboard | |
| Real Time Insider Trading Transactions | |
| 8,000+ Institutional investors’ 13F holdings | |
| Powerful Excel Add-in and Google sheets Add-on | |
| All data downloadable | |
| Quick customer support | |
| And much more... |
Trustpilot
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
